Human IgG subclasses against enterovirus Type 71: neutralization versus antibody dependent enhancement of infection

PLoS One. 2013 May 20;8(5):e64024. doi: 10.1371/journal.pone.0064024. Print 2013.

Abstract

The emerging human enterovirus 71 (EV71) represents a growing threat to public health, and no vaccine or specific antiviral is currently available. Human intravenous immunoglobulin (IVIG) is clinical used in treating severe EV71 infections. However, the discovery of antibody dependent enhancement (ADE) of EV71 infection illustrates the complex roles of antibody in controlling EV71 infection. In this study, to identify the distinct role of each IgG subclass on neutralization and enhancement of EV71 infection, different lots of pharmaceutical IVIG preparations manufactured from Chinese donors were used for IgG subclass fractionation by pH gradient elution with the protein A-conjugated affinity column. The neutralization and ADE capacities on EV71 infection of each purified IgG subclass were then assayed, respectively. The neutralizing activity of human IVIG is mainly mediated by IgG1 subclass and to less extent by IgG2 subclass. Interestingly, IgG3 fraction did not have neutralizing activity but enhanced EV71 infection in vitro. These results revealed the different roles of human IgG subclasses on EV71 infection, which is of critical importance for the rational design of immunotherapy and vaccines against severe EV71 diseases.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Neutralizing / isolation & purification
  • Antibodies, Neutralizing / physiology*
  • Antibodies, Viral / isolation & purification
  • Antibodies, Viral / physiology*
  • Cell Line, Tumor
  • Enterovirus A, Human / immunology*
  • Enterovirus Infections / immunology*
  • Enterovirus Infections / virology
  • Host-Pathogen Interactions
  • Humans
  • Immunoglobulin G / isolation & purification
  • Immunoglobulin G / physiology*
  • Neutralization Tests

Substances

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Immunoglobulin G

Grants and funding

This work was supported by Beijing Natural Science Foundation (numbers 7112108 and 7122129), and National Natural Science Foundation of China (numbers 81000721 and 31270195). C.F. Qin was supported by the Beijing Nova Program of Science and Technology (number 2010B041). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.